LUND, SWEDEN / ACCESSWIRE / November 05, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported preclinical results...
HOUSTON, Nov. 4, 2024 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...
LOS ANGELES, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered...
SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company using in-vivo click chemistry to enable pre-targeting...
LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit...
Trial builds upon promising evidence of clinical activity of TTX-080 when combined cetuximab, presented at ASCO 2024SOUTH SAN FRANCISCO, Calif.,...
SEATTLE WA AND LUND, SWEDEN / ACCESSWIRE / October 29, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB...
RMAT Designation Follows Positive Proof-of-Concept Data from the ALLO-316 TRAVERSE Trial in Adult Patients with Advanced or Metastatic CD70 Positive...
Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding...
BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...
ST. LOUIS, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. a clinical-stage biotech company focused on the discovery and development...
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumabBASKING RIDGE, N.J., Oct....
WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage...
Oslo, October 25, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that...
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s multi-center Phase...
SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell...